Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.32 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9517894 | 0.82 | CYP2C9 (0.37) | CYP2C9MAPTALDH1A1LMNAOPRL1 | |
| SCHEMBL9514174 | 0.76 | MAPT (0.32) | CYP2C9MAPTALDH1A1LMNAOPRL1 | |
| SCHEMBL9516779 | 0.75 | CYSLTR2 (0.35) | CYP2C9MAPTMEN1KMT2ACYSLTR2 | |
| SCHEMBL8045323 | 0.75 | CYP2C9 (0.34) | CYP2C9MAPTALDH1A1LMNAOPRL1 | |
| SCHEMBL7510560 | 0.75 | CYP2C9 (0.34) | CYP2C9MAPTALDH1A1LMNAOPRL1 | |
| SCHEMBL9513977 | 0.75 | CYP2C9 (0.36) | CYP2C9MAPTALDH1A1LMNAOPRL1 | |
| SCHEMBL9516412 | 0.75 | CYSLTR2 (0.36) | ALDH1A1CYSLTR2CYSLTR1 | |
| SCHEMBL9515658 | 0.75 | CYSLTR2 (0.36) | ALDH1A1CYSLTR2CYSLTR1 | |
| SCHEMBL9518034 | 0.75 | CYSLTR2 (0.36) | ALDH1A1CYSLTR2CYSLTR1 | |
| SCHEMBL9514070 | 0.75 | CYSLTR2 (0.36) | ALDH1A1CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3673521-B1 | DIELECTRIC LAYER COMPRISING COPOLYMER WITH MESOGENIC UNITS | PPG IND OHIO INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-11525087-B2 | Dielectric devices and methods of fabrication | PPG INDUSTRIES OHIO, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20200263092-A1 | DIELECTRIC DEVICES AND METHODS OF FABRICATION | PPG INDUSTRIES OHIO, INC. | 2020-08-20 | — | — | US | disclosed |
| EP-3673521-A1 | DIELECTRIC LAYER COMPRISING COPOLYMER WITH MESOGENIC UNITS | PPG Industries Ohio, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10619099-B2 | Dielectric devices and methods of fabrication | PPG INDUSTRIES OHIO, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| WO-2019040934-A1 | DIELECTRIC LAYER COMPRISING COPOLYMER WITH MESOGENIC UNITS | PPG INDUSTRIES OHIO, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| EP-2686401-B9 | MESOGEN-CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2686401-B1 | MESOGEN-CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-2686401-A1 | MESOGEN-CONTAINING COMPOUNDS | Transitions Optical, Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8628685-B2 | Mesogen-containing compounds | TRANSITIONS OPTICAL, INC (US) | 2014-01-14 | — | — | US | disclosed |
| WO-2012128944-A1 | MESOGEN-CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20110216273-A1 | MESOGEN-CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110216273-A1 | MESOGEN-CONTAINING COMPOUNDS | BMP2, MYOC, RARG | CYP2C9 2756/4885MAPT 2276/4885ALDH1A1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.